

Investor Webinar Presentation

Melbourne, Australia, November 13, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday 14th November 2023, 1:00pm AEDT/ 10:00am AWST.

CEO, Steven Lydeamore will provide an overview and update on the business and upcoming milestones.

Following the presentation, attendees will have the opportunity to ask questions directly to Mr Lydeamore during a moderated Q & A session.

This webinar can be viewed live via zoom & you register via the link below.

Zoom: https://share.hsforms.com/1ccfJimCATYqzCkvIKIC7VAd16zr

A recorded copy of the webinar will be made available following the event.

Authorised for release by the Board of Immuron Limited.

- - - END - - -

COMPANY CONTACT:

Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com

About Travelan®

Travelan[®] is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveller's diarrhoea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan[®] is a highly purified tabletised preparation of hyperimmune bovine antibodies and other factors, which when taken with meals bind to diarrhoea-causing bacteria and prevent colonisation and the pathology associated with traveller's diarrhoea. In Australia, Travelan[®] is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveller's Diarrhoea, reduce the risk of minor gastrointestinal disorders and is antimicrobial. In Canada, Travelan[®] is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveller's Diarrhoea. In the U.S., Travelan[®] is sold as a dietary supplement for digestive tract protection.

About Traveller's Diarrhoea

Traveller's Diarrhoea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic *Escherichia coli* (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with Traveller's Diarrhoea as they may be contracted while travelling and initial symptoms are often indistinguishable.



About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com

FORWARD-LOOKING STATEMENTS:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.







WATCHLIST WEBINAR PRESENTATION

14 NOVEMBER, 2023

Steven Lydeamore - CEO

NASDAQ: IMRN ASX: IMC

SAFE HARBOR STATEMENT

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

FY2024 results in this presentation are subject to audit review.



Immur@n

REVENUE GENERATING WITH STRONG PIPELINE



Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases


Financial Snapshot						
Shares on Issue	227,798,346					
Total Options	14,568,559					
Last Traded Price	IMC: A\$0.075					
52 week High/Low	IMC: A\$0.105 / 0.067 IMRN: \$3.21 / 1.39					
Market Cap	IMC: A\$17.08m					
Cash & Cash Equivalents (30 June 2023)	A\$17.2m					

Major Shareholders					
Units	% of CSO				
78,644,465	34.5 %				
6,904,554	3.0 %				
6,000,000	2.6 %				
3,846,712	1.7 %				
	Units 78,644,465 6,904,554 6,000,000				

IMMUr@n

DISTRIBUTION CAPABILITY





IMMUr@n

STRONG SALES GROWTH IN ATTRACTIVE MARKET





Traveller's Diarrhoea (TD)

Market is large and growing ~7% ³ CAGR

Industry tailwinds

Travel picking up significantly following COVID lockdowns

Frequent

30% - 70% of travelers experience TD ⁴



Net Sales FY23: A\$1.16 million 1QFY24: A\$1.35 million 229% higher than prepandemic period 1QFY20

IMMUr@n

Net Sales FY23: **A\$0.64 million** 1QFY24: A\$0.21 million 9% lower than prepandemic period 1QFY20

Australia

12 months to July 2023 short term resident returns 77% of those in 2019¹ USA **Total departures** June 2023 99.4% of June 2019²

Chief Commercial Officer has 20+ year's experience with local and global (Asia, UK) commercial leadership roles with GSK and P&G

\$83m

Based on US annual travel numbers and a penetration rate of 15%, the market potential is estimated at \$83m 5

\$50m

Based on EU travel numbers and a penetration rate of 15%, the market potential is estimated at \$50m 5


1. https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release https://www.trade.gov/sites/default/files/2023-09/US-Outbound-to-World-Regions.xlsx 3. Research Reports World, 28 May 2021: Global Traveler's Diarrhea Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2021-2027

4. Centers for Disease Control and Prevention Yellow Book 5. IMC Company Report - Travelan Market Analysis 2019

TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES

Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk. This enables full development of the newborn calf in addition to immunity against several pathogens.^{*}

Immuron's proprietary technology platform *combines the natural human nutrition* & *health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies* that offer delivery within the gastrointestinal ("GI") tract and can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces.




- ✓ Reduce occurrence and reduce/relieve diarrhoea
- ✓ Reduce/relieve abdominal cramping
- ✓ Reduce/relieve gastrointestinal pain
- ✓ Assists repair of gastrointestinal/gut wall lining
- ✓ Enhance/promote immune defence
- ✓ Enhance/promote health liver function

Australian Permitted indications; these statements have not been evaluated by the Food and Drug Administration (FDA)



7

STRONG PIPELINE WITH NEAR TERM MILESTONES



Further information on the clinical programs can be found on slide 8

VALUABLE SALES POTENTIAL FOR PIPELINE PRODUCTS

- Immuron's development of **IMM-124E** (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need
- Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80% protection against the development of diarrhea.
- If base case efficacy targets are reached, IMM-124E would mostly be used by travelers going to the highest risk areas (e.g., rural Central America/Asia/Africa).

Opportunity

Lumanity*

- Based on the estimated market size and pricing, the base case yearly revenue in USA for IMM-124E is projected at **US\$102M**.
- Assessment for IMIM-124E Reaching higher efficacy goals could broaden use.

Compound or brand name	Indication		
IMM-124E - Travelan®	Traveler's Diarrhea ETEC challenge		
IMM-529	Clostridioides difficile Infection & Recurrence		

- Infectious disease experts reacted favorably to the IMM-529 MOA, and its unique ability to target three elements of the rCDI infection – the spores, vegetative cells, and Toxin B
- Non-microbiome approaches (such as IMM-529) are still appealing to experts, who noted that clinical trial efficacy (reduction in relapse rate) and cost/access will be the key drivers of clinical use in recurrent patients, not mechanism of action
- Based on the estimated market size, anticipated payer restrictions, pricing, and competition, base case yearly revenue in USA for IMM-529 is conservatively projected at US\$93M for the target patient population (limited to 2nd recurrence and later based on trial design and payer coverage)

Positioning IMM-529 earlier than second recurrence and/or > efficacy targets could lead to higher uptake.



Lumanity, a leading lifescience consulting company: https://lumanity.com/company/our-story/

Assessment for IMM-529

Lumanity Opportunity

Clostridioides difficile infections (CDI) to grow to almost \$1.7 billion by 2026, according to GlobalData

NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE



		2H 2022		1H 2023	2H 2023		1H 2024
Travelan®	•	FDA IND ¹ approved for single daily dose IMM-124E ETEC ² CHIM ³ clinical trial	•	IRB Approval ⁴ • Initiated IMM-124E ETEC ² CHIM ³ • clinical trial	100% of patients enrolled Completion of In-patient phase ETEC ² CHIM ³ clinical trial	•	Topline results for IMM-124E ETEC ² clinical trial Clinical Study Report
CampETEC	•	Submitted Response Letter to FDA Clinical Hold Immuron sponsored Toxicology study - completed	•	Toxicology Study Report•FDA IND1 approved (Clinical Hold released)•	Institutional Review Board approval of NMRC ⁵ CampETEC Campylobacter CHIM ³ clinical trial protocol FDA approval of IND amendment for change to protocol	•	Initiate NMRC ⁵ CampETEC Campylobacter CHIM ³ clinical trial Completion of In-patient phase CampETEC Campylobacter CHIM ³ clinical trial
IMM-529	•	600 mg solid dose active formulation development		•	IMM-529 cGMP manufacture	•	IMM-529 (CDI) ⁷ Pre-IND ¹ submission
Travelan®	•	USU ⁶ P2TD IMM-124E field clinical trial recruitment commencement		•	~50% of 868 participants recruited	•	Completion of enrollment Completion of in-patient phase

IMMUI©U

Completed; 1. Investigational New Drug; 2. Enterotoxigenic *E.coli*; 3. controlled human infection model; 4. Institutional Review Board; 5. Naval Medical Research Command; 6. Uniformed Health Services University of the Health Sciences; 7. Clostridioides Difficile 10





Immur@n

STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED

CONTACT INFORMATION:



EMAIL: <u>STEVE@IMMURON.COM</u>



PHONE: AUSTRALIA: +613 8892 4854

SCIENTIFIC REFERENCES



Travelan[®] (IMM-124E)

Travelan [®] has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% of volunteers	Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726
Clinical Evaluation of Travelan [®] an Oral Prophylactic for Prevention of Travelers' Diarrhea in Active Duty Military Service Assigned Abroad.	Military Health System Research Symposium 14-17 Aug 2023 Abstract 1
Travelan as a broad Spectrum anti-bacterial	Immuron Limited, 29 April, 2011
Travelan [®] demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler's diarrhea	US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 4 September, 2019
Travelan [®] prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan [®] treated animals compared to placebo and demonstrated a significant clinical benefit	US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 5 September, 2018
Travelan [®] able to bind and was reactive to 60 clinical isolates of each bacteria, Campylobacter, ETEC, and Shigella	US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 30 January, 2017
Efficacy of hyperimmune bovine colostrum against shigellosis in rhesus macaque (Macaca mulatta), and bioactivity of HBC against common enteric pathogens	Islam et al., 2020. Submitted to mSphere, American Society for Microbiology
Bioactive Immune Components of Travelan®	Clin Vaccine Immunol 24:e00186-16. https://doi.org/10.1128/CVI.00186-16
Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM-124E) has a non-detrimental effect on gut microbial communities in unchallenged mice	Rachele Gore, Mitra Mohsenipour, Jennifer L Wood, Gayathri K Balasuriya, Elisa L Hill-Yardin, Ashley E Franks
Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis	Journal of Crohn's and Colitis, Volume 13, Issue 6, June 2019, Pages 785–797, https://doi.org/10.1093/ecco-jcc/jjy213

IMM-529

Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative

Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5